Cidofovir: Difference between revisions
From IDWiki
(→) |
(→) |
||
| Line 1: | Line 1: | ||
==Background== |
==Background== |
||
| + | *Acyclic nucleoside phosphonate that competes with cytosine nucleotides to inhibit viral DNA polymerase |
||
| − | *Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]] |
||
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
||
| Line 21: | Line 21: | ||
*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]] |
*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]] |
||
| − | [[Category: |
+ | [[Category:Acyclic nucleoside phosphonates]] |
Revision as of 13:55, 11 September 2020
Background
- Acyclic nucleoside phosphonate that competes with cytosine nucleotides to inhibit viral DNA polymerase
- Indications: Adenovirus, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus
Spectrum of Activity
- Active against essentially all DNA viruses, including polyomaviruses (BK virus, JC virus), human papillomavirus, adenovirus, all of the human herpesviruses, poxviruses (including monkeypox virus and variola virus)
- Not active against hepatitis B virus or RNA viruses
Pharmacokinetics and Pharmacodynamics
- Unlike ganciclovir, it does not need phosphorylation by UL97
Dosing
- Should be given with probenecid 2 g IV prior to each dose
Safety
- Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid
